The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 837-842

  Takigawa, Nagio ^a,b   Takeyama, Masako ^a   Shibayama, Takuo ^a   Tada, Atsuhiko ^a   Kawata, Noriko ^a   Okada, Chiharu ^a   Aoe, Keisuke ^c   Kozuki, Toshiyuki ^b   Hotta, Katsuyuki ^b   Tabata, Masahiro ^b   Kiura, Katsuyuki ^b   Ueoka, Hiroshi ^c   Tanimoto, Mitsune ^b   Takahashi, Kiyoshi ^a  

^a Department of Internal Medicine   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL SANYO HOSPITAL   (Japan)

Author keywords

Amrubicin; Cisplatin; Irinotecan; Median effect plot analysis; Small cell lung cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; AMRUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; IC 50; LUNG TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS;

EID: 33746390166     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.837     Document Type: Article

References (26)

1. Doyle LA: Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20: 326-337, 1993.
2. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002. (Pubitemid 34438898)
3. Ishizumi K, Ohashi N and Tanno N: Streospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 50: 4477-4485, 1987. (Pubitemid 18061289)
4. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T and Yanagi Y: Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89: 1061-1067, 1998.
5. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T and Yamaoka T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89: 1229-1238, 1998. (Pubitemid 29008005)
6. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y and Fukui M: Antitumor activities of a novel 9-aminoanthracycline (SM5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80: 69-76, 1989. (Pubitemid 20027201)
7. Suzuki T, Minamide S, Iwasaki T, Yamamoto H and Kanda H: Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15: 219-225, 1997. (Pubitemid 27453876)
8. Noda T, Watanabe T, Kohda A, Hosokawa S and Suzuki T: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16: 121-128, 1998. (Pubitemid 28495213)
9. Yana T, Negoro Y, Takada S, Yokota M and Fukuoka M: Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group Trial. Proc Am Soc Clin Oncol 17: 450, 1998.
10. Miyamoto H: Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 40: 65-73, 1986.
11. Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, Ueoka H, Ohnoshi T and Tanimoto M: Establishment of a 7-ethyl-10-hydroxy-camptothecin- resistant human small-cell lung cancer cell line. Anticancer Res 24: 3911-3916, 2004. (Pubitemid 40468685)
12. Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T and Harada M: Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 18: 927-933, 1998. (Pubitemid 28239618)
13. Ahmed SA, Gogal RM Jr and Walsh JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170: 211-224, 1994. (Pubitemid 24122510)
14. Chang TT and Chou TC: Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan 41: 294-302, 2000.
15. Chou TC and Talaly P: A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252: 6438-6442, 1977. (Pubitemid 8193791)
16. Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, Matsushita A, Kohara H and Harada M: Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 19: 291-299, 1999. (Pubitemid 29168252)
17. Kiura K, Ohnoshi T, Tabata M, Shibayama T and Kimura I: Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance. Acta Med Okayama 47: 191-197, 1993.
18. Takigawa N, Ohnoshi T, Ueoka H, Kiura K and Kimura I: Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46: 203-212, 1992.
19. Takigawa N, Ohnoshi T, Ueoka H, Kiura K and Kimura I: Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. Acta Med Okayama 46: 249-256, 1992.
20. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M and Ariyoshi Y: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer. Ann Oncol 16: 430-436, 2005. (Pubitemid 40458320)
21. Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, Uchida A, Bessho A, Segawa Y, Shinkai T, Nogami N, Harita S, Okimoto N, Ueoka H and Tanimoto M: Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 25: 2429-2434, 2005. (Pubitemid 41044726)
22. Takagi T, Yazawa Y, Suzuki K, Yamauchi Y and Kano Y: Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines. Invest New Drugs 14: 357-363, 1996. (Pubitemid 27075442)
23. Yamauchi S, Kudoh S, Kimura T, Hirata K and Yoshikawa J: Additive effects of amrubicin with cisplatin on human lung cancer cell lines. Osaka City Med J 48: 69-76, 2002.
24. Rubin EH, Li TK, Duann P and Liu LF: Cellular resistance to topoisomerase poisons. Cancer Treat Res 87: 243-260, 1996.
25. Xu Y and Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851, 2002. (Pubitemid 36040772)
26. Mitsuoka S, Kudoh S, Takada Y, Matsui K, Eguchi K, Ichinose Y, Nakagawa K, Takada M, Saito H and Ariyoshi Y: Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG9902. Proc Am Soc Clin Oncol 22: 7044, 2004.